-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Yinnuo Pharmaceutical-B (02591.HK) announced that the Group's core product (i.e. esparglutide α) has been successfully included in China's latest “National Medical Insurance Drug Catalogue” (2025 edition) to treat type 2 diabetes (“T2D”) indications. The latest version of the “National Medical Insurance Drug Catalogue” will officially come into effect on January 1, 2026.

Zhitongcaijing·12/07/2025 11:25:02
Listen to the news
Zhitong Finance App News, Yinnuo Pharmaceutical-B (02591.HK) announced that the Group's core product (i.e. esparglutide α) has been successfully included in China's latest “National Medical Insurance Drug Catalogue” (2025 edition) to treat type 2 diabetes (“T2D”) indications. The latest version of the “National Medical Insurance Drug Catalogue” will officially come into effect on January 1, 2026.